Immunotherapy eradicates metastases with reversible defects in MHC class I expression

Area of Science:

• Immunology
• Cancer Biology
• Oncology

Background:

• Tumor cells often downregulate MHC class I (MHC-I) expression to evade immune surveillance during cancer progression.
• MHC-I defects can be reversible (soft lesions) or irreversible (hard lesions), potentially influencing immunotherapy outcomes.
• The study investigates the role of MHC-I alterations in determining the efficacy of antitumor treatments.

Purpose of the Study:

• To evaluate the capacity of different antitumor treatments to inhibit spontaneous metastatic colonization.
• To investigate the impact of reversible MHC-I alterations on treatment response.
• To analyze the effects of immunotherapy on host immunosuppression in a murine fibrosarcoma model.

Main Methods:

• Utilized an MHC-I-positive murine fibrosarcoma tumor clone (GR9-A7) that forms lung and lymph node metastases.
• Administered four different antitumor treatments post-primary tumor excision, including immunotherapy, chemoimmunotherapy, and chemotherapy alone.
• Employed flow cytometry to analyze lymphocyte populations and assess host immunosuppression.

Main Results:

• Two immunotherapy protocols (CpG plus irradiated GR9-A7 cells, and protein-bound polysaccharide K (PSK)) and one chemoimmunotherapy (docetaxel plus PSK) eradicated metastases.
• Chemotherapy with docetaxel alone resulted in only a partial reduction in metastatic burden.
• Immunotherapy treatments reverted the observed immunosuppression in GR9-A7 tumor-bearing hosts.

Conclusions:

• Reversible or irreversible MHC-I alterations in tumor cells may dictate cancer progression or regression.
• Immunotherapy, but not chemotherapy alone, effectively eradicated metastases in this model.
• The nature of MHC-I alterations appears to be a critical factor in determining treatment success, independent of the specific immunotherapy used.